Completed PHASE2 INTERVENTIONAL NCT00083421

Effects of ONO-2506PO in Patients With Alzheimer's Disease

Sponsor: Ono Pharma USA Inc

Interventions ONO-2506PO

Updated 6 times since 2017 Last updated: Jun 12, 2012 Started: Jun 30, 2004 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Alzheimer's Disease and is currently completed. Ono Pharma USA Inc leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ono Pharma USA Inc

Data source: Ono Pharmaceutical Co. Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Alexandria, United States , Atlanta, United States , Bellaire, United States , Bennington, United States , Birmingham, United States , Boca Raton, United States , Chicago, United States , Cleveland, United States , Columbus, United States and 65 more locations